Under a deal that depends on Novartis AG's big, pending asset swap with Glaxosmithkline plc (GSK), the BRAF inhibitor encorafenib (also known as LGX818) – stranded with Novartis since December, when the pharma giant returned MEK blocker binimetinib rights to Array Biopharma Inc. – is joining its sister at Array, and the phase III combination trial called COLUMBUS in BRAF-positive melanoma (encorafenib's fate in which had been unsure), will go on.